Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
Amandine Le Bourgeois, Marianne Coste‐Burel, Thierry Guillaume, Pierre Péterlin, Alice Garnier, Marie C. Béné, Patrice Chevallier
Abstract
This cohort study examines safety and antibody responses after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant (HSCT).
Topics & Concepts
Antibody responseHaematopoiesisHematopoietic stem cell transplantationMedicineHematopoietic stem cellMessenger RNAAntibodyStem cellVirologyImmunologyTransplantationBiologyInternal medicineGeneticsGeneSARS-CoV-2 and COVID-19 ResearchImmunotherapy and Immune ResponsesRNA Interference and Gene Delivery